Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glycaemic Fluctuations with Insulin Glargine vs NPH
NCT00322075Phase 4Completed
- Sponsor
- Sanofi
- Start
- Apr 2006
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of insulin glargine in type 1 diabetes mellitus (T1D) and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Sanofi. Primary endpoints: 3 days continual glycaemic profile fluctuation, Occurrence of adverse events and 5 more. Started Apr 2006; status: completed.
02
Drugs
insulin glargine
03
Conditions
type 1 diabetes mellitus (T1D)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00322075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00322075.